Estrogen Deprivation Therapy and Colon Cancer Risk in Breast Cancer Patients

David O. Malaka MBBS, MPH

Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medical Center, Chicago, Illinois

Olufunmilayo I. Olopade MD, FACP

Professor of Medicine and Human Genetics, Director, Cancer Risk Clinic, The University of Chicago Medical Center, Chicago, Illinois

Search for more papers by this author

David O. Malaka MBBS, MPH,

David O. Malaka MBBS, MPH

Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medical Center, Chicago, Illinois

Search for more papers by this author

Olufunmilayo I. Olopade MD, FACP,

Olufunmilayo I. Olopade MD, FACP

Professor of Medicine and Human Genetics, Director, Cancer Risk Clinic, The University of Chicago Medical Center, Chicago, Illinois

Search for more papers by this author

First published: 08 January 2010

https://doi.org/10.1111/j.1524-4741.2009.00862.x

Address correspondence and reprint requests to: David O. Malaka, MBBS, MPH, Postdoctoral Research Fellow, Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medical Center, 5841 S. Maryland Avenue, MC 2115, Chicago, Illinois 60637, or e-mail: [email protected].

Share a link

Email
Wechat
Bluesky

References

1 Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst 2007; 99: 727–37.
10.1093/jnci/djk154
CAS PubMed Web of Science® Google Scholar
2 Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95. Lancet 2005; 366: 455–62.
10.1016/S0140-6736(05)67059-6
CAS PubMed Web of Science® Google Scholar
3 The ATAC Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7: 633–43.
10.1016/S1470-2045(06)70767-7
CAS PubMed Web of Science® Google Scholar
4 Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 2007; 25: 2664–70.
10.1200/JCO.2006.08.8054
CAS PubMed Web of Science® Google Scholar
5 Rutquist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995; 87: 645–51.
10.1093/jnci/87.9.645
PubMed Web of Science® Google Scholar
6 Newcomb PA, Solomon C, White E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat 1999; 53: 271–7.
10.1023/A:1006117220284
CAS PubMed Web of Science® Google Scholar
7 Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83: 1013–7.
10.1093/jnci/83.14.1013
CAS PubMed Web of Science® Google Scholar
8 Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerman DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527–37.
10.1093/jnci/86.7.527
CAS PubMed Google Scholar
9 Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996; 88: 832–4.
PubMed Web of Science® Google Scholar
10 Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652–62.
10.1093/jnci/dji372
CAS PubMed Web of Science® Google Scholar
11 Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574–82.
10.1016/S0002-9343(99)00063-7
CAS PubMed Web of Science® Google Scholar

All articles

Estrogen Deprivation Therapy and Colon Cancer Risk in Breast Cancer Patients

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Estrogen Deprivation Therapy and Colon Cancer Risk in Breast Cancer Patients

References

References

Related

Information